Amgen Inc. (USD) Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Amgen Inc. (USD) Active

One Amgen Center Drive, Thousand Oaks, CA, US, 91320-1799

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

AMGN's stock peer is BMY (Bristol-Myers Squibb Company)

AMGN's stock peer is BSX (Boston Scientific Corporation)

AMGN's stock peer is DHR (Danaher Corporation)

AMGN's stock peer is GILD (Gilead Sciences, Inc.)

AMGN's stock peer is MRK (Merck & Co., Inc.)

AMGN's stock peer is NVO (Novo Nordisk A/S)

Healthcare Drug Manufacturers - General

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

100%

Dcf Rating

100%

Return On Equity

100%

Return On Assets

20%

Debt To Equity

40%

Price To Earnings

20%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-05-15	2026-06-05	2.52	3.00 %	Quarterly
2026-02-13	2026-03-06	2.52	2.62 %	Quarterly
2025-11-21	2025-12-12	2.38	2.82 %	Quarterly
2025-08-22	2025-09-12	2.38	3.20 %	Quarterly
2025-05-16	2025-06-06	2.38	3.40 %	Quarterly
2025-02-14	2025-03-07	2.38	3.14 %	Quarterly
2024-11-18	2024-12-09	2.25	3.23 %	Quarterly
2024-08-16	2024-09-06	2.25	2.76 %	Quarterly
2024-05-17	2024-06-07	2.25	2.78 %	Quarterly
2024-02-16	2024-03-07	2.25	2.99 %	Quarterly
2023-11-17	2023-12-08	2.13	3.17 %	Quarterly
2023-08-18	2023-09-08	2.13	3.16 %	Quarterly
2023-05-18	2023-06-08	2.13	3.62 %	Quarterly
2023-02-15	2023-03-08	2.13	3.30 %	Quarterly
2022-11-17	2022-12-08	1.94	2.73 %	Quarterly
2022-08-18	2022-09-08	1.94	3.02 %	Quarterly
2022-05-17	2022-06-08	1.94	3.03 %	Quarterly
2022-02-15	2022-03-08	1.94	3.22 %	Quarterly
2021-11-16	2021-12-08	1.76	3.39 %	Quarterly
2021-08-17	2021-09-08	1.76	2.98 %	Quarterly
2021-05-17	2021-06-08	1.76	2.67 %	Quarterly
2021-02-15	2021-03-08	1.76	2.79 %	Quarterly
2020-11-16	2020-12-08	1.60	2.70 %	Quarterly
2020-08-17	2020-09-08	1.60	2.61 %	Quarterly
2020-05-18	2020-06-08	1.60	2.54 %	Quarterly
2020-02-14	2020-03-06	1.60	2.67 %	Quarterly
2019-11-15	2019-12-06	1.45	2.65 %	Quarterly
2019-08-15	2019-09-06	1.45	2.85 %	Quarterly
2019-05-17	2019-06-07	1.45	3.26 %	Quarterly
2019-02-15	2019-03-08	1.45	2.90 %	Quarterly
2018-11-16	2018-12-07	1.32	2.74 %	Quarterly
2018-08-17	2018-09-07	1.32	2.60 %	Quarterly
2018-05-17	2018-06-08	1.32	2.84 %	Quarterly
2018-02-15	2018-03-08	1.32	2.66 %	Quarterly
2017-11-17	2017-12-08	1.15	2.69 %	Quarterly
2017-08-17	2017-09-08	1.15	2.62 %	Quarterly
2017-05-17	2017-06-08	1.15	2.69 %	Quarterly
2017-02-15	2017-03-08	1.15	2.48 %	Quarterly
2016-11-16	2016-12-08	1.00	2.73 %	Quarterly
2016-08-17	2016-09-08	1.00	2.17 %	Quarterly
2016-05-17	2016-06-08	1.00	2.35 %	Quarterly
2016-02-16	2016-03-08	1.00	2.38 %	Quarterly
2015-11-16	2015-12-07	0.79	2.09 %	Quarterly
2015-08-17	2015-09-08	0.79	1.77 %	Quarterly
2015-05-14	2015-06-05	0.79	1.77 %	Quarterly
2015-02-12	2015-03-06	0.79	1.72 %	Quarterly
2014-11-13	2014-12-05	0.61	1.50 %	Quarterly
2014-08-14	2014-09-05	0.61	1.82 %	Quarterly
2014-05-15	2014-06-06	0.61	1.95 %	Quarterly
2014-02-13	2014-03-07	0.61	1.67 %	Quarterly
2013-11-14	2013-12-06	0.47	1.67 %	Quarterly
2013-08-16	2013-09-06	0.47	1.66 %	Quarterly
2013-05-16	2013-06-07	0.47	1.54 %	Quarterly
2013-02-13	2013-03-07	0.47	1.83 %	Quarterly
2012-11-15	2012-12-07	0.36	1.68 %	Quarterly
2012-08-16	2012-09-07	0.36	1.63 %	Quarterly
2012-05-16	2012-06-07	0.36	1.82 %	Quarterly
2012-02-15	2012-03-07	0.36	1.35 %	Quarterly
2011-11-17	2011-12-08	0.28	0.99 %	Quarterly
2011-08-18	2011-09-08	0.28	0.55 %	Quarterly

Recent News

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 14, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation.

2026-06-14 20:01:00

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.

2026-06-07 16:45:00

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m.

2026-06-04 16:01:00

AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis THOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.

2026-06-03 09:00:00

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.

2026-05-29 16:01:00

Ember LifeSciences announces new strategic investments boosting Series A to $27M

LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN ) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.

2026-05-27 09:00:00

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020.

2026-05-19 16:05:00

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.

2026-05-07 16:01:00

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR

Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.

2026-05-04 09:00:00

AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.

2026-04-30 16:01:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions